Citations Appearing in 1997

  1. Acosta, E.P., K. Henry, L.M. Page, A. Erice, H.H. Balfour and C.V. Fletcher. Pharmacokinetics and safety of concentration controlled oral Zidovudine therapy. Pharmacotherapy 17:424-430, 1997.
  2. Amantea, M.A., A. Forrest, D.W. Northfelt and R. Mamelok. Population pharmacokinetics and pharmacodynamics of pegylated liposomal doxorubicin in patients with AIDS related kaposis sarcoma. Clinical Pharmacology and Therapeutics 61:301-311, 1997.
  3. Amsden, G.W., C.H. Ballow and A. Forrest. Comparison of the plasma, urine and blister fluid pharmacokinetics of Clarithromycin and Azithromycin in normal subjects. Clinical Drug Investigation 13:152-161, 1997.
  4. Bauer, J.A., J.P. Balthasar and H.L. Fung. Application of pharmacodynamic modeling for designing time variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure. Pharmaceutical Research 14(9):1140-1145, 1997.
  5. Bauer, R.J., K. Der, N. Ottah-Ihejeto, J. Barrientos and A.H.C Kung. The role of liver and kidney on the pharmacokinetics of a recombinant amino terminal of bactericidal/permeability-increasing protein in rats. Pharmaceutical Research14(2):224- 229, 1997.
  6. Burstein, A.H., P. Gal and A. Forrest. Evaluation of a sparse sampling strategy for determining Vancomycin pharmacokinetics in preterm neonates application of optimal sampling theory. Annals of Pharmacotherapy 31:980-983, 1997.
  7. Chattergoon, D.S., E.F. Saunders, J. Klein, S. Calderwood, J. Doyle, M.H. Freedman and G. Koren. An improved limited sampling method for individualized Busulfan dosing in bone marrow transplantation in children. Bone Marrow Transplantation 20:347-354, 1997.
  8. Cheng, H.Y., Y.M. Gong and W.J. Jusko. A computer program using disposition decomposition analysis in pharmacodynamics. Biopharmaceutics and Drug Disposition 18:9-15, 1997.
  9. Conley, B.A., M.J. Egorin, R. Sridhara, R. Finley, R. Hemady, S. Wu, N.S. Tait and D.A. Van Echo. Phase I clinical trial of all-trans-retinoic acid with correlation of pharmacokinetics and pharmacodynamics. Cancer Chemotherapy and Pharmacology 39:291-299, 1997.
  10. Cornwell, E.E., H. Belzberg, T.V. Berne, M.A. Gill, D. Theodorou, J.W. Kern, W. Yu, J. Asensio and D. Demetriades. Pharmacokinetics of Aztreonam in critically ill surgical patients. American Journal of Health System Pharmacy 54:537-540, 1997.
  11. Duddu, S.P., A. Khinkhin, D.J.W. Grant and R. Suryanarayanan. A novel X-ray powder diffractometric method for studying the reaction between pseudoephedrine enantiomers. Journal of Pharmaceutical Sciences 86:340-345, 1997.
  12. Dutta, S. and W.F. Ebling. Parameter estimability of biphasic response models. Journal of Pharmaceutical Sciences 86:44-51, 1997.
  13. Dutta, S., Y. Matsumoto and W.F. Ebling. Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor El formulation. Journal of Pharmaceutical Sciences 86:967-969, 1997.
  14. Dutta, S., Y. Matsumoto, N.U. Gothgen and W.F. Ebling. Concentration – EEG effect relationship of propofol in rats. Journal of Pharmaceutical Sciences 86:37-43, 1997.
  15. Ebling, W.F., Y. Matsumoto and G. Levy. Feasibility of effect controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data. Pharmaceutical Research 13:1804-1810, 1997.
  16. Errecalde, J.O., N. Mestorino and E.L. Marino. The effects of the method of calculation on the evaluation of the pharmacokinetic parameters of oxytetracycline after intravenous administration to calves. Veterinary Research Communications 21:273- 281, 1997.
  17. Fletcher, C.V., B.K. Goodroad, L.M. Cummins, K. Henry, H.H. Balfour and F.S. Rhame. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. AntimicrobialAgents and Chemotherapy 41:1571- 1574, 1997.
  18. Forrest, A., S. Chodosh, M.A. Amantea, D.A. Collins and J.J. Schentag. Pharmacokinetics and pharmacodynamics of oral Grepafloxacin in patients with acute bacterial exacerbations of chronic-bronchitis. Journal of Antimicrobial 40:45-57, 1997.
  19. Fujiwara, Y., T. Takahashi, M. Yamakido, T. Ohune, T. Tsuya and M.J. Egorin. Prediction of Carboplatin clearance from standard morphological and biological patient characteristics. Journal of the National Cancer Institute 89:260-261, 1997.
  20. Gillespie, W.R. Convolution-based approaches for in vivo in vitro correlation modeling. In Vitro-In Vivo Correlations 423:53-65, 1997.
  21. Gruber, S.A., M. Gallichio, T.G. Rosano, S.S. Kaplan, S.E. Hughes, D.L. Urbauer, T.P. Singh, N. Lempert, D.J. Conti, D.S. Stein and G. Drusano. Comparative pharmacokinetics and renal effects of cyclosporine-A and cyclosporine-G in renal allograft recipients. Journal of Clinical Pharmacology 37:575-586, 1997.
  22. Haberkorn, U., M.E. Bellemann, A. Altmann, L. Gerlach, I. Morr, F. Oberdorfer, G. Brix, J. Doll, J. Blatter and G. Vankaick. Pet 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with Gemcitabine. Journal of Nuclear Medicine 38:1215-1221, 1997.
  23. Haidar, S.H., J.E. Moreton, Z.M. Liang, J.F. Hoke, K.T. Muir and N.D. Eddington. The pharmcokinetics and electroencephalogram response of Remifentanil alone and in combination with Esmolol in the rat. Pharmaceutical Research 14:1817-1823, 1997.
  24. Kaplan, D.D., L.E. Williams, K.G. Clarke et al: Estimating residence times and their associated errors in patient absorbed dose calculation. Journal of Nuclear Medicine25:264-268, 1997.
  25. Ko, H.C., W.J. Jusko and W.F. Ebling. Nonlinear perpendicular least-squares regression in pharmacodynamics. Biopharmaceutics and Drug Disposition 18(8):711-716, 1997.
  26. Koehntop, D.E. and J.H. Rodman. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 17:746-752, 1997.
  27. Kohn, E.C., W.D. Figg, G.A. Sarosy, K.S. Bauer, P.A. Davis, M.J. Soltis, A. Thompkins, L.A. Liotta and E. Reed. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors – pharmacokinetics, clinical outcome, and comparison of formulations. Journal of Clinical Oncology 15:1985-1993, 1997.
  28. Kramer, T.H., H. Bartoszbechowski, P. Davis, V.J. Hruby and F. Porreca. Extraordinary potency of a novel delta opioid receptor agonist is due in part to increased efficacy. Life Sciences 61:129-135, 1997.
  29. Kumar, S., G.R. Tonn, E. Kwan, C. Hall, K.W. Riggs, J.E. Axelson and D.W. Rurak. Estimation of transplacental and nonplacental diphenhydramine clearances in the fetal lamb – the impact of fetal first pass hepatic drug uptake. Journal of Pharmacology and Experimental Therapeutics 282:617-632, 1997.
  30. Lambert, J.S., L.M. Mofenson, C.V. Fletcher, J. Moye, E.R. Stiehm, W.A. Meyer, G.J. Nemo, B.J. Mathieson, G. Hirsch, C.V. Sapan, L.M. Cummins, E. Jimenez, E. Oneill, A. Kovacs and A. Stek. Safety and pharmacokinetics of hyperimmune antihuman immunodeficiency virus (HIV) immunoglobulin administered to HIV infected pregnant women and their newborns. Journal of Infectious Diseases 175:283-291, 1997.
  31. Mahmood, I. A comparative computer simulation study of 3 different sparse sampling methods for the estimation of steady state area under the concentration time curve (AUC) and maximum concentration (C-Max) in toxicokinetics. Journal of Pharmaceutical Sciences 86:579-583, 1997.
  32. Malhotra, B.K., R.C. Brundage, M. Lemaire and R.J. Sawchuk. Modeling the route of administration based enhancement in the brain delivery of Eab-515, studied by microdialysis. Journal of Drug Targeting 4:277-288, 1997.
  33. Marro, P.J., S. Baumgart, M. Delivoriapapadopoulos, S. Zirin, L. Corcoran, S.P. Mcgaurn, L.E. Davis and R.R. Clancy. Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation. Pediatric Research 41:513-520, 1997.
  34. Mckindley, D.S., B.A. Boucher, M.M. Hess, J.H. Rodman, C. Feler and T.C. Fabian. Effect of acute phase response on phenytoin metabolism in neurotrauma patients. Journal of Clinical Pharmacology 37:129-139, 1997.
  35. Merle, Y. and F. Mentre. Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models – application in pharmacokinetics. Mathematical Biosciences 144:45-70, 1997.
  36. Miyazaki, M., Y. Fujiwara, T. Takahashi, t. Isobe, T. Ohune, T.Tsuya and M. Yamakido. Limited-sampling models for estimation of the Carboplatin area-under-thecurve. Anticancer Research 17:4571-4575, 1997.
  37. Morley Forster, P., J.D. McAllister, H. Vandenberghe, J.J. Thiessen, A. White, M. Taylor and D.C. Knoppert. Does Thiopentone delay recovery in children premedicated with Midazolam? Paediatric Anaesthesia 7(4):279-285, 1997.
  38. Nix, D.E., J.H. Wilton, J. Hyatt, J. Thomas, L.C. Strenkoskinix, A. Forrest and J.J. Schentag. Pharmacodynamic modeling of the in-vivo interaction between Cefotaxime and Ofloxacin by using serum ultrafiltrate inhibitory titers. Antimicrobial Agents and Chemotherapy 41:1108-1114, 1997.
  39. Odom-Maryon, T.L., L.E. Williams, A. Chai, G. Lopatin, A. Liu, J.Y.C. Wong, J. Chou, K.G. Clarke and A.A. Raubitschek. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans. Journal of Nuclear Medicine 38:1959-1966, 1997.
  40. Peloquin, C.A., G.S. Jaresko, C.L. Yong, A.C.F. Keung, A.E. Bulpitt and R.W. Jelliffe. Population pharmacokinetic modeling of Isoniazid, Rifampin, and Pyrazinamide. Antimicrobial Agents and Chemotherapy 41(12):2670-2679, 1997.
  41. Peng B., M.W. English, A.V. Boddy, L. Price, R. Wyllie, A.D.J. Pearson, M.J. Tilby and D.R. Newell. Cisplatin pharmacokinetics in children with cancer. European Journal of Cancer 33(11):1823-1828, 1997.
  42. Phair, R.D. Development of kinetic-models in the nonlinear world of molecular cell biology. Metabolism-Clinical and Experimental 38:1959-1966, 1997.
  43. Piscitelli, S.C., W.D. Figg, B. Hahn, G. Kelly, S. Thomas and R.E. Walker. Single dose pharmacokinetics of Thalidomide in human immunodeficiency virus infected patients. Antimicrobial Agents and Chemotherapy 41(12):2797-2799, 1997.
  44. Piscitelli, S.C., A. Forrest, R.M. Lush, N. Ryan, L.R. Whitfield and W.D. Figg. Pharmacometric analysis of the effect of Furosemide on Suramin pharmacokinetics. Pharmacotherapy 17:431-437, 1997.
  45. Polis, M.A., S.C. Piscitelli, S. Vogel, F.G. Witebsky, P.S. Conville, B. Petty, J.A. Kovacs, R.T. Davey, R.E. Walker, J. Falloon, J.A. Metcalf, C. Craft, H.C. Lane and H. Masur. Clarithromycin lowers plasma Zidovudine levels in persons with humanimmunodeficiency-virus infection. Antimicrobial Agents and Chemotherapy 41:1709- 1714, 1997.
  46. Proost, J.H., J. Roggeveld, J.M.K.H. Wierda and D.K.F. Meijer. Relationship between chemical structure and physicochemical properties of series of bulky organic cations and their hepatic uptake and biliary excretion rates. Journal of Pharmacology and Experimental Therapeutics 282:715-726, 1997.
  47. Pui, C.H., J.M. Boyett, W.T. Hughes, G.K. Rivera, M.L. Hancock, J.T. Sandlund, T. Synold, M.V. Relling, R.C. Ribeiro, W.M. Crist and W.E. Evans. Human granulocyte colony stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. New England Journal of Medicine 336:1781-1787, 1997.
  48. Ramanathan, M. A physiochemical modeling approach for estimating the stability of soluble receptor bound tumor necrosis factor alpha. Cytokine 9:19-26, 1997.
  49. Roberts, B.J., K.E. Hook, L.R. Whitfield, C.A. Carter and W.L. Elliott. Clinically relevant Suramin dosing regimen in mice with no effects against PC-3 prostate xenografts. Oncology Reports 4(6):1361-1366, 1997.
  50. Rosner, G.L. and P. Muller. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models. Journal of Pharmacokinetics and Biopharmaceutics 25(2):209-233, 1997.
  51. Salazar, D.E., D.R. Much, P.S. Nichola, J.R. Seibold, D. Shindler and P.H. Slugg. A pharmacokinetic pharmacodynamic model of D-Sotalol Q-Tc prolongation during intravenous administration to healthy subjects. Journal of Clinical Pharmacology 37:799-809, 1997.
  52. Samara, E. and R. Granneman. Role of population pharmacokinetics in drug development – a pharmaceutical industry perspective. Clinical Pharmacokinetics 32:294-312, 1997.
  53. Siddiqui, N., A.V. Boddy, H.D. Thomas, N.P. Bailey, L. Robson, M.J. Lind and A.H. Calvert. A clinical and pharmacokinetic study of the combination of Carboplatin and Paclitaxel for epithelial ovarian cancer. British Journal of Cancer 75:287-294, 1997.
  54. Soraci, A.L., N. Mestorino and J.O. Errecalde. Some pharmacokinetic parameters of Oxfendazole in sheep. Veterinary Research Communications 21:283-287, 1997.
  55. Sparacino, G. and C. Cobelli. Impulse response model in reconstruction of insulin secretion by deconvolution – role of input design in the identification experiment. Annals of Biomedical Engineering 25:398-416, 1997.
  56. Stein, D.S. and G.L. Drusano. Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Antimicrobial Agents and Chemotherapy 41:449-453, 1997.
  57. Stevens R.C., Reed M.D., Shenep J.L., Foulds G., Luke D.R. and Rodman J.H. Pharmacokinetics of Azithromycin following single and mutiple dosing in children. Pharmacotherapy 17(5):874-880, 1997.
  58. Stewart, C.F., W.C. Zamboni, W.R. Crom and P.J. Houghton. Disposition of Irinotecan and Sn-38 following oral and intravenous Irinotecan dosing in mice. Cancer Chemotherapy and Pharmacology 40:259-265, 1997.
  59. Sun, H., E.I. Ette and T.M. Ludden. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 24:637-650, 1997.
  60. Tai, H.L., E.Y. Krynetski, E.G. Schuetz, Y. Yanishevski and W.E. Evans. Enhanced proteolysis of thiopurine S-methyltransferase (Tpmt) encoded by mutant alleles in humans (Tpmt-Asterisk-3A, Tpmt-Asterisk-2) – mechanisms for the genetic polymorphism of Tpmt activity. Proceedings of the National Academy of Sciences of the United States of America 94:6444-6449, 1997.
  61. Thompson, J., W.C. Zamboni, P.J. Cheshire, L. Lutz, X.L. Luo, Y.L. Li, J.A. Houghton, C.F. Stewart and P.J. Houghton. Efficacy of systemic administration of Irinotecan against neuroblastoma xenografts. Clinical Cancer Research 3(3):423-431, 1997.
  62. Timpone, J.G., D.J. Wright, N. Li, M.J. Egorin, M.E. Enama, J. Mayers, G. Galetto, S. Gagnon, J. Vargo, K. Chirgwin, A. Marcel, D. Cohn, B. Hopkins, M. Dudley, S. Geletko, H. Standiford, K. Cervino, D.M. Mushatt, D. Greenspan, W. Powderly, M. Meyers, J.H. Sampson, G. Mcmillan, R. Novak and L. Moreira. The safety and pharmacokinetics of single agent and combination therapy with megestrol acetate and Dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses 13:305-315, 1997.
  63. Tod, M. and J.M. Rocchisani. Comparison of Ed, Eid, and API criteria for the robust optimization of sampling times in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 25:515-537, 1997.
  64. Toutain, P.L. and G.D. Koritz. Veterinary drug bioequivalence determination. Journal of Veterinary Pharmacology and Therapeutics 20:79-90, 1997.
  65. Uckun, F.M., Y. Yanishevski, N. Tumer, B. Waurzyniak, Y. Messinger Y, L.M. Chelstrom, E.A. Lisowski, O. Ek, T. Zeren, H. Wendorf, M.C. Langlie, J.D. Irvin, D.E. Myers, G.B. Fuller, W. Evans and R. Gunther. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Clinical Cancer Research 3(3):325-337, 1997.
  66. Ursino, M. and C.A. Lodi. A simple mathematical model of the interaction between intracranial pressure and cerebral hemodynamics. Journal of Applied Physiology 82:1256-1269, 1997.
  67. Ursino, M., C.A. Lodi, S. Rossi and N. Stocchetti. Intracranial pressure dynamics in patients with acute brain damage. Journal of Applied Physiology 82:1270-1282, 1997.
  68. Utoguchi, N., Y.Watanabe, T. Suzuki, J. Maehara, Y. Matsumoto and M. Matsumoto. Carrier mediated transport of monocarboxylic acids in primary cultured epithelial cells from rabbit oral mucosa. Pharmaceutical Research 14:320-324, 1997.
  69. Verotta, D. Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Critical Reviews in Biomedical Engineering 24:73-139, 1997.
  70. Wattanatorn, W., H.L. Mcleod, F. Macklon, M. Reid, K.E. Kendle and J. Cassidy. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer. Pharmacotherapy 17(5):881-886, 1997.
  71. Waurzyniak, B., E.A. Schneider, N. Tumer, Y. Yanishevski, R. Gunther, L.M. Chelstrom, H. Wendorf, D.E. Myers, J.D. Irvin, Y. Messinger, O. Ek, T. Zeren, M.C. Langlie, W.E. Evans and F.M. Uckun. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (Anti-CD7)-pokeweed antiviral protein immunotoxin. Clinical Cancer Research 3(6):881-890, 1997.
  72. Weiss, M., C. Stedtler and M.S. Roberts. On the validity of the dispersion model of hepatic drug elimination when intravascular transit time densities are long tailed. Bulletin of Mathematical Biology 59:911-929, 1997.
  73. Wong, J.Y.C., G.E. Thomas, D. Yamauchi, L.E. Williams, T.L. Odommaryon, A. Liu, J.M. Esteban, M. Neumaier, S.Dresse, A.M. Wu, F.J. Primus, J.E Shively and A.A. Raubitschek. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonalantibody. Journal of Nuclear Medicine 38:1951-1959, 1997.
  74. Wu, G. Use of a 5-compartment closed model to describe the effects of ethanol inhalation on the transport and elimination of injected pyruvate in the rat. Alcohol and Alcoholism 32(5):555-561, 1997.
  75. Wu, G. Using a 4 compartment closed model to describe inhalation of vaporised ethanol on 1-c-14-pyruvate kinetics in mice. Archives of Toxicology 71:501-507, 1997.
  76. Yule, S.M., N.K. Foreman, C. Mitchell, N. Gouldon, P. May and H.P. Mcdowell. High dose Cyclophosphamide for poor prognosis and recurrent pediatric brain tumors – a dose escalation study. Journal of Clinical Oncology 15(10):3258-3265, 1997.